Advanced search
Publication Cover
Leukemia & Lymphoma Volume 64, 2023 - Issue 2
Submit an article Journal homepage
144
Views
1
CrossRef citations to date
0
Altmetric
Articles

External validation of a heart failure risk score in patients with acute myeloid leukemia

Peter G. Doukasa Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USAORCID Iconhttps://orcid.org/0000-0001-6242-5395
ORCID Icon,
Gregory J. Cascinob Division of Cardiovascular Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
,
Zhiying Mengb Division of Cardiovascular Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
,
Abigail S. Baldridgeb Division of Cardiovascular Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
,
Yu Kangc Division of Cardiovascular Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
,
Marielle Scherrer-Crosbiec Division of Cardiovascular Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
&
Nausheen Akhterb Division of Cardiovascular Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-9423-8578
ORCID Icon show all
Pages 445-453 | Received 23 Jun 2022, Accepted 11 Oct 2022, Published online: 04 Nov 2022

References

  • Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021. CA A Cancer J Clin. 2021;71(1):7–33.
  • Sturgeon KM, Deng L, Bluethmann SM, et al. A population-based study of cardiovascular disease mortality risk in US cancer patients. Eur Heart J. 2019;40(48):3889–3897.
  • Zaorsky NG, Churilla TM, Egleston BL, et al. Causes of death among cancer patients. Ann Oncol. 2017;28(2):400–407.
  • Yates JW, Wallace HJ Jr., Ellison RR, et al. Cytosine arabinoside (NSC-63878) and daunorubicin (NSC-83142) therapy in acute nonlymphocytic leukemia. Cancer Chemother Rep. 1973;57(4):485–488.
  • Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003;97(11):2869–2879.
  • Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979;91(5):710–717.
  • Zamorano JL, Lancellotti P, Rodriguez Munoz D, et al. 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(36):2768–2801.
  • Raval P, Kota V, Zakharia Y, et al. Congestive heart failure (CHF) in acute myeloid leukemia patients during induction. J Clin Oncol. 2013;31(15_suppl):7105.
  • Mort MK, Sen JM, Morris AL, et al. Evaluation of cardiomyopathy in acute myeloid leukemia patients treated with anthracyclines. J Oncol Pharm Pract. 2020;26(3):680–687.
  • Herrmann J, Lerman A, Sandhu NP, et al. Evaluation and management of patients with heart disease and cancer: cardio-oncology. Mayo Clin Proc. 2014;89(9):1287–1306.
  • Kang Y, Assuncao BL, Denduluri S, et al. Symptomatic heart failure in acute leukemia patients treated with anthracyclines. JACC Cardiooncol. 2019;1(2):208–217.
  • Haji K, Marwick TH. Clinical utility of echocardiographic strain and strain rate measurements. Curr Cardiol Rep. 2021;23(3):18.
  • Hicks KA, Mahaffey KW, Mehran R, et al. 2017 Cardiovascular and stroke endpoint definitions for clinical trials. Circulation. 2018;137(9):961–972.
  • Long-term follow-up guidelines for survivors of childhood, adolescent and young adult cancers, Version 5.0. Children’s Oncology Group; 2018 [cited 2022]. Available from: http://www.survivorshipguidelines.org/
  • Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28(1):1–39 e14.
  • Lyon AR, Dent S, Stanway S, et al. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. Eur J Heart Fail. 2020;22(11):1945–1960.
  • Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2017;35(8):893–911.
  • Cardinale D, Colombo A, Bacchiani G, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015;131(22):1981–1988.
  • Shah A, Andersson TM, Rachet B, et al. Survival and cure of acute myeloid leukaemia in England, 1971–2006: a population-based study. Br J Haematol. 2013;162(4):509–516.
  • Rose-Inman H, Kuehl D. Acute leukemia. Hematol Oncol Clin North Am. 2017;31(6):1011–1028.
  • Assuncao B, Handschumacher MD, Brunner AM, et al. Acute leukemia is associated with cardiac alterations before chemotherapy. J Am Soc Echocardiogr. 2017;30(11):1111–1118.
  • Sengelov M, Jorgensen PG, Jensen JS, et al. Global longitudinal strain is a superior predictor of all-cause mortality in heart failure with reduced ejection fraction. JACC Cardiovasc Imaging. 2015;8(12):1351–1359.
  • Zhang KW, French B, May Khan A, et al. Strain improves risk prediction beyond ejection fraction in chronic systolic heart failure. J Am Heart Assoc. 2014;3(1):e000550.
  • Stanton T, Leano R, Marwick TH. Prediction of all-cause mortality from global longitudinal speckle strain: comparison with ejection fraction and wall motion scoring. Circ Cardiovasc Imaging. 2009;2(5):356–364.
  • DiNardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133(1):7–17.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.